EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies

Keong Chong iD, Jack Keng-Jui Chang, Lee-Ming Chuang

The Kaohsiung Journal of Medical Sciences · 2024

DOI: 10.1002/kjm2.12800 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2024. Verfasst von Keong Chong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several recent advances provide multiple health benefits to individuals with type 2 diabetes mellitus (T2DM). Pharmacological therapy is governed by person‐centered factors, including comorbidities and treatment goals. Adults with T2DM who have an established/high risk of atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease, require a treatment regimen that includes agents that are proven to reduce cardiorenal risk. Weight management plays a key role in reducing glucose for patients with T2DM. A glucose‐reduction treatment regimen must consider weight management. Sodium glucose co‐transporter 2 (SGLT2) inhibitors reduce the risk of heart failure, cardiovascular and renal events. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists allow better control of glycemia, promote weight loss and reduce the risk of cardiovascular events. Newer Glucose‐dependent insulinotropic polypeptide (GIP) and GLP‐1 dual agonist, which activate GIP and GLP‐1 receptors improve glycemic control and promote greater weight loss than GLP‐1 receptor agonists. Several novel drugs are in the clinical development phase. This review pertains to recent advances in pharmacological management of type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsHeart FailureAdultHumansHypoglycemic AgentsGlucagon-Like Peptide 1GlucoseWeight Loss

Stichwörter der Autor:innen

glucagon-like peptide-1 (GLP-1) receptor agonistsinsulin icodecretatrutidesodium glucose co-transporters 2 (SGLT2) inhibitorstirzepatide

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide 1Sodium-Glucose Transporter 2 InhibitorsGlucose

Autor:innen und Institutionen

  • Department of Internal Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan.
  • Department of Nursing, Yuanpei University of Medical Technology, Hsinchu, Taiwan.
  • Biological Programs for Younger Scholar, Academia Sinica, Taipei, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

ORCID-Profile: Keong Chong

Zitieren

APA

Chong, K., Chang, J. K., & Chuang, L. M. (2024). Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.12800

Vancouver

Chong K, Chang JK, Chuang LM. Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies. The Kaohsiung Journal of Medical Sciences. 2024. doi:10.1002/kjm2.12800

BibTeX
@article{Chong2024,
  author = {Chong, Keong and Chang, Jack Keng-Jui and Chuang, Lee-Ming},
  title = {Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies},
  journal = {The Kaohsiung Journal of Medical Sciences},
  year = {2024},
  doi = {10.1002/kjm2.12800}
}
Kostenlos starten →